FUNDAMENTAL AND CLINICAL STUDIES ON CEFIXIME

• Published in: CHEMOTHERAPY Vol. 33; no. Supplement6; pp. 638 - 649
• Main Authors: AKINO, HIRONOBU, OKANO, MANABU, ISOMATSU, YUKISHIGE, MURANAKA, KOJI, KANIMOTO, YUSUKE, SHIMIZU, YASUO, KAWADA, YUKIMICHI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1985
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.33.Supplement6_638

The usefullness of cefixime (CFIX), a new oral cephalosporin, in urinary tract infection (UTI) was studied in bacteriological and clinical aspects. The antibacterial activities of CFIX against E. coli (31 strains), Citrobacter spp.(16 strains), K. pneumoniae (32 strains), Enterobacter spp.(16 strains), S. marcescens (21 strains), P. mirabilis (27 strains) and Indole (+) Proteus (27 strains), all of which were isolated from urinary tract, were examined. Although the antibacterial activity of CFIX against Citrobacter spp. was not so high in comparison with cephalexin, cefaclor and amoxicillin, CFIX showed higher antibacterial activities against other species, especially against Enterobacter spp., S. marcescens and Indole (+) Proteus, most of which were resistant to cephalexin, cefaclor and amoxicillin. Clinically, 9patients with acute uncomplicated cystitis (AUC), 11 patients with chronic complicated cystitis (CCC) and 2 patients with gonococcal urethritis (GU) were treated with daily doseof 100 to 200mg of CFIX. The effectiveness rates of 100% in AUC, 91% in CCC and 100% in GU were obtained. Moreover, the effectiveness rate of 6 CCC outpatients who were matched to the criteria of UTI committee was 100%, and this drug was observed to be effective in patients with indwelling catheter who were infected with single organism. Bacteriologically, except for 2 strains of S. marcescens, all bacteria isolated before treatment were eradicated. Neither side effects nor aggravation in laboratory tests results were observed. These results indicate CFIX may be effective in UTI with high safety.